Supplementary Figure S6 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects

Figure S6. Best response, earliest time point, duration of best response, previous PARPi exposure, platinum sensitivity, biomarker status, and duration of treatment in the prostate (A, B), colorectal (C, D), and breast (E, F) cancer dose-expansion cohorts, and best response, biomarker status, and duration of treatment in the alternative-schedule dose-escalation cohorts (G–J)